BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 32372238)

  • 1. Treatment of Aggressive B Cell Lymphomas: Updates in 2019.
    Mondello P; Nowakowski GS
    Curr Hematol Malig Rep; 2020 Jun; 15(3):225-234. PubMed ID: 32372238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [CAR-T cells in lymphomas: Current and evolving role].
    Messéant O; Houot R
    Bull Cancer; 2021 Oct; 108(10S):S28-S39. PubMed ID: 34920805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas.
    Reagan PM; Friedberg JW
    Future Oncol; 2021 Apr; 17(11):1269-1283. PubMed ID: 33448873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Doraiswamy A; Shah MR; Bannerji R
    Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.
    Zelenetz AD; Gordon LI; Abramson JS; Advani RH; Bartlett NL; Caimi PF; Chang JE; Chavez JC; Christian B; Fayad LE; Glenn MJ; Habermann TM; Lee Harris N; Hernandez-Ilizaliturri F; Kaminski MS; Kelsey CR; Khan N; Krivacic S; LaCasce AS; Mehta A; Nademanee A; Rabinovitch R; Reddy N; Reid E; Roberts KB; Smith SD; Snyder ED; Swinnen LJ; Vose JM; Dwyer MA; Sundar H
    J Natl Compr Canc Netw; 2019 Jun; 17(6):650-661. PubMed ID: 31200358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Classification and Treatment of Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma.
    Roschewski M; Phelan JD; Wilson WH
    Cancer J; 2020; 26(3):195-205. PubMed ID: 32496453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment strategies for patients with diffuse large B-cell lymphoma.
    Poletto S; Novo M; Paruzzo L; Frascione PMM; Vitolo U
    Cancer Treat Rev; 2022 Nov; 110():102443. PubMed ID: 35933930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR T cell therapy for B-cell lymphomas.
    Chavez JC; Locke FL
    Best Pract Res Clin Haematol; 2018 Jun; 31(2):135-146. PubMed ID: 29909914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Therapies in the Treatment of Adult Acute Lymphoblastic Leukemia.
    Gavralidis A; Brunner AM
    Curr Hematol Malig Rep; 2020 Aug; 15(4):294-304. PubMed ID: 32445026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
    Camicia R; Winkler HC; Hassa PO
    Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas.
    Trabolsi A; Arumov A; Schatz JH
    Blood Cancer J; 2024 Feb; 14(1):27. PubMed ID: 38331870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.
    Xu-Monette ZY; Li J; Xia Y; Crossley B; Bremel RD; Miao Y; Xiao M; Snyder T; Manyam GC; Tan X; Zhang H; Visco C; Tzankov A; Dybkaer K; Bhagat G; Tam W; You H; Hsi ED; van Krieken JH; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; Winter JN; Medeiros JT; Xu B; Li Y; Kirsch I; Young KH
    J Immunother Cancer; 2019 Oct; 7(1):272. PubMed ID: 31640780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
    Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
    Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult Acute Lymphoblastic Leukemia in the Modern Era of Immune Therapy.
    Yurkiewicz I; Craig J; Muffly L
    Curr Hematol Malig Rep; 2020 Jun; 15(3):187-193. PubMed ID: 32358681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric Antigen Receptor-Engineered T-Cells - A New Way and Era for Lymphoma Treatment.
    Mihăilă RG
    Recent Pat Anticancer Drug Discov; 2019; 14(4):312-323. PubMed ID: 31642414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden.
    Qu C; Ping N; Kang L; Liu H; Qin S; Wu Q; Chen X; Zhou M; Xia F; Ye A; Kong D; Li C; Yu L; Wu D; Jin Z
    J Immunother; 2020 Jan; 43(1):32-37. PubMed ID: 31219975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers.
    Inthagard J; Edwards J; Roseweir AK
    Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frontline treatment of diffuse large B-cell lymphoma: Beyond R-CHOP.
    Mondello P; Mian M
    Hematol Oncol; 2019 Oct; 37(4):333-344. PubMed ID: 30938848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic effects of chimeric antigen receptor T cells (CAR-T) on relapse/refractory diffuse large B-cell lymphoma (R/R DLBCL): a meta-analysis.
    Cao HH; Wang LL; Geng CK; Mao WW; Yang LL; Ma Y; He M; Zhang R; Zhou YY; Liu LQ; Hu XJ; Yu JX; Yang L; Shen XF; Yin LF; Gu XZ; Shen ZL
    Eur Rev Med Pharmacol Sci; 2020 May; 24(9):4921-4930. PubMed ID: 32432755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in Supportive Care for Acute Lymphoblastic Leukemia.
    Cook J; Litzow M
    Curr Hematol Malig Rep; 2020 Aug; 15(4):276-293. PubMed ID: 32607955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.